Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Samsung Biologics separates CDMO and biosimilars with new holding company Samsung Bioepis Holdings aims to enhance corporate ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...